Gene transfer for congestive heart failure: update 2013

被引:5
|
作者
Tang, Tong
Hammond, H. Kirk
机构
[1] Univ Calif San Diego, Dept Med, San Diego, CA 92161 USA
[2] VA San Diego Healthcare Syst, San Diego, CA USA
基金
美国国家卫生研究院;
关键词
LEFT-VENTRICULAR FUNCTION; SARCOPLASMIC-RETICULUM CA2+-ATPASE; ADENYLYL-CYCLASE EXPRESSION; FAILING HUMAN HEARTS; CARDIAC-DIRECTED EXPRESSION; CA2+-BINDING PROTEIN S100A1; ADRENERGIC-RECEPTOR KINASE; IN-VIVO; ADENOASSOCIATED VIRUS; INTRACORONARY DELIVERY;
D O I
10.1016/j.trsl.2012.11.004
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Congestive heart failure is a major cause of morbidity and mortality with increasing social and economic costs. There have been no new high impact therapeutic agents for this devastating disease for more than a decade. However, many pivotal regulators of cardiac function have been identified using cardiac-directed transgene expression and gene deletion in preclinical studies. Some of these increase function of the failing heart. Altering the expression of these pivotal regulators using gene transfer is now either being tested in clinical gene transfer trials, or soon will be. In this review, we summarize recent progress in cardiac gene transfer for clinical congestive heart failure. (Translational Research 2013;161:313-320)
引用
收藏
页码:313 / 320
页数:8
相关论文
共 50 条